TONGRENTANGCM (Hong Kong Stock Exchange: 03613) 2021 performance bucks the trend and rises Net profit reached HK$651 million, overseas business revenue increased by 30.6%

HONG KONG SAR – Media OutReach – 19 April 2022 – Traditional Chinese medicine has played an important role in the prevention and control of the epidemic in recent years. In addition, the national policy has vigorously promoted the development of the industrial chain. Tongrentang, which has a brand history of more than 300 years, is actively seizing development opportunities. TONGRENTANGCM (03613), which is rooted in the Hong Kong market, revealed in its recently announced 2021 annual results announcement that its net profit reached HK$651 million, with its overseas market business revenue growing at a rapid rate of 30.6% against the trend. Both local and overseas business revenue in Hong Kong maintained high growth under the epidemic, demonstrating a stable business strategy and strong overseas development potential.

Meanwhile, TONGRENTANGCM also took the initiative to offer purchase discounts on anti-epidemic products to many Chinese institutions and launched a special package of Ganoderma lucidum spore powder capsules to provide the public with more choices of anti-epidemic products. Currently, it is also planning to donate Antigen Rapid Test kits for COVID-19 to many nursing homes in Hong Kong, so that the elderly with limited mobility can also conduct self-testing, and further checking the epidemic situation in Hong Kong.

Website︰https://cm.tongrentang.com/

This press release is issued by Beijing Tongrentang Chinese Medicine Co., Ltd.

The issuer is solely responsible for the content of this announcement.